 | Up a level |
2018
Smith, M. R., Parker, C. C., Saad, F., Miller, K., Tombal, B., Ng, Q. S., Boegemann, M., Matveev, V., Piulats, J. M., Zucca, L. E., Heidenreich, A., Kakehi, Y., Zhang, A., Krissel, H., Shen, J., Wagner, V. and Higano, C. (2018). ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naive patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC). Ann. Oncol., 29. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
2015
Wolf, J., Schneider, C-P, Potzner, M., Arratia, Cazorla P., Shen, J., Branle, F. and von Pawel, J. (2015). The phase II ASCEND-7 (CLDK378A2205) trial: Ceritinib in patients (pts) with ALK-rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) metastatic to the brain and/or leptomeninges. Oncol. Res. Treat., 38. S. 138 - 139. BASEL: KARGER. ISSN 2296-5262